News
-

Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-

Sermorelin Half-Life: Minutes, Not Hours
Sermorelin leaves the bloodstream in minutes, but the growth-hormone pulse it starts can last for hours. Those are two different clocks, and neither is a personal dosing or drug-testing deadline.
-

Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
-

Where to Inject MOTS-c: What the Evidence Says
The available human trial records point to a subcutaneous shot into the fatty layer beneath the skin. The pharmacy label and prescriber—not an online injection map—set the site for a specific MOTS-c preparation.
-

Compounded Tirzepatide Side Effects: What Changes?
Most side effects come from tirzepatide itself. Compounding can add a second layer of risk through concentration, measurement, added ingredients, sterility, and potency.
-

Does Tesamorelin Build Muscle? What Trials Show
Tesamorelin raised lean mass modestly in trials of adults with HIV-related lipodystrophy, but that is not proof of bigger or stronger muscles. It has not been shown to build muscle in healthy lifters.
-

Oral TB-500: Why Capsules Lack Human Evidence
There is no human evidence that a TB-500 capsule delivers intact peptide into the bloodstream. The published TB-500 and thymosin beta-4 work used injected or topical routes, so a capsule label cannot prove absorption or an effect.
-

Semaglutide Before and After: An Honest Timeline
The first month is usually an adjustment period, month six is still part of the active curve, and a plateau often comes much later. Photos cannot show the treatment, timing, or follow-up behind a change.
-

Semax Selank Nasal Spray: What the Route Changes
A Semax Selank nasal spray puts both peptides in one intranasal liquid, but there is no universal recipe. The route, concentration, pump, and prescription all matter—the Russian studies used nasal drops and sprays, while the blend Promise offers by prescription is an injectable vial.
-

SS-31 Protocol: What the Trials Actually Used
There is no single SS-31 cycle supported by human research. The useful evidence is narrower: a labeled plan for one rare disease and several trial schedules that cannot be copied into personal dosing advice.
-

Tesamorelin Before and After: The Study Timeline
Expect an early lab signal, not a one-month change in the mirror. The strongest trials measured deep abdominal fat at 26 and 52 weeks, all in adults with HIV-associated lipodystrophy.
-

Tirzepatide for Seniors: What New 2026 Data Show
Age 65 alone does not rule out tirzepatide. New 2026 research is reassuring, but adults over 75 remain underrepresented and the safest decision turns on muscle reserve, hydration, kidney health and other medicines.
-

When to Take Sermorelin: Why Bedtime Is Common
Bedtime is the usual convention because the body's largest growth-hormone pulse often follows deep sleep. It is a rhythm to work with, not proof that one clock time fits everyone.
-

DSIP Nasal Spray: What the Human Research Says
A DSIP nasal spray appears in one small human experiment, but no published human nasal PK or sleep trial validates the format. Promise currently lists DSIP as an injection, not a spray.
-

Generic Semaglutide Exists—Just Not in the U.S.
Canada now has authorized semaglutide generics. The U.S. has only a tentative approval, while compounded semaglutide is another category altogether.
-

Is Tesamorelin a Steroid? No—It's a GHRH Peptide
Tesamorelin is a peptide signal, not an anabolic steroid or growth hormone itself. It prompts the pituitary to release growth hormone, but sport rules still prohibit it.
-

Kisspeptin vs PT-141: They Work Differently
Kisspeptin and PT-141 both enter libido conversations, but they act on different systems and do not share the same evidence. PT-141 has larger trials and an approved branded product; kisspeptin's human data are smaller and earlier.
-

Orforglipron Is Approved: What Foundayo Changes
Orforglipron is now sold as Foundayo, a once-daily GLP-1 pill for weight management. It removes the fasting rules of oral semaglutide, but it does not replace every reason someone may choose an injection.
-

Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-

Sermorelin Before and After: A Research Timeline
The research shows hormone changes within weeks, not a predictable visible transformation. Here is what small adult studies measured at two, six, and 16 weeks.
Page 14 of 27 · 528 articles